Complications and Management of Myocardial Infarction in Hypertensive Patients: A Review

Azhari Gani; Kemala Hayati

doi:10.24815/jds.v9i1.40338

Complications and Management of Myocardial Infarction in Hypertensive Patients: A Review

Azhari Gani, Kemala Hayati

Abstract

Background: Myocardial infarction (MI) and hypertension are cardiovascular conditions that frequently coexist and influence each other. Hypertension not only increases the risk of MI but also complicates its clinical management. Therefore, it is crucial to understand the complications arising from this condition and the effective management strategies. Objectives: This systematic review aims to identify and analyze common complications in hypertensive patients experiencing MI and evaluate the optimal management approaches based on the latest literature. Methods: A literature search was conducted in electronic databases such as PubMed, Scopus, and Google Scholar using relevant keywords like "myocardial infarction," "hypertension," "complications," and "management." Articles published in the last five years were selected to ensure the most current information. Inclusion criteria included observational studies, clinical trials, and systematic reviews relevant to the topic. Data were extracted and analyzed descriptively. Results: Of the 1500 articles identified, 45 studies met the inclusion criteria. Major complications found in hypertensive patients with MI included heart failure, arrhythmias, stroke, and left ventricular dysfunction. The most effective management approaches included appropriate use of antihypertensive medications, early reperfusion interventions, and a multidisciplinary approach to controlling cardiovascular risk factors. The use of ACE inhibitors, beta-blockers, and aldosterone antagonists proved to have significant benefits in reducing morbidity and mortality. Conclusions: Complications of myocardial infarction in hypertensive patients require comprehensive and coordinated management. Effective management involves a combination of pharmacological and non-pharmacological therapies focusing on optimal blood pressure control and prevention of further complications. Further research is needed to explore more specific and personalized management strategies in this population.

Keywords

Myocardial Infarction, Hypertension, Complications, Management, Cardiovascular Risk

Full Text:

PDF

References

Gehani AA, Al-Hinai AT, Zubaid M, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. European journal of preventive cardiology 2014;21(4):400-10.

Fernandes T, Roque FR, Soci UPR, Melo SFS, de Oliveira EM. Exercise training in hypertension: Role of microRNAs. World journal of cardiology 2014;6(8):713.

Wright GA. Prevalence of Left Ventricular Hypertrophy in Peripheral Arterial Disease and Its Relation to Blood Pressure [University of Dundee; 2014.

Yusuf S, McKee M. Documenting the global burden of cardiovascular disease: a major achievement but still a work in progress: Am Heart Assoc; 2014. p. 1459-62.

Caligiuri S. The reduction of hypertension through dietary flaxseed intervention and the identification of oxylipins as therapeutic targets in cardiovascular disease. 2014.

Webb AJS. Determinants of medium-term blood pressure variability and the related risks of stroke and dementia [University of Oxford; 2014.

Corban MT, Hung OY, Eshtehardi P, et al. Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies. Journal of the American College of Cardiology 2014;63(22):2346-55.

Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunologic research 2014;59:243-53.

Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014;64(5):1012-21.

Jugdutt BI, Jelani A, Abualnaja S, Sharma NC, Wong JS. Reperfusion and Vasodilator Therapy in Elderly Patients with STEMI and Heart Failure: Improving Outcomes. Aging and Heart Failure: Mechanisms and Management: Springer; 2014. p. 199-220.

Nguyen HL, Nguyen QN, Ha DA, et al. Prevalence of comorbidities and their impact on hospital management and short-term outcomes in Vietnamese patients hospitalized with a first acute myocardial infarction. PloS one 2014;9(10):e108998.

Moras E, Yakkali S, Gandhi KD, et al. Complications in Acute Myocardial Infarction: Navigating Challenges in Diagnosis and Management. Hearts 2024;5(1):122-41.

Maile MD, Engoren MC, Tremper KK, Jewell E, Kheterpal S. Worsening preoperative heart failure is associated with mortality and noncardiac complications, but not myocardial infarction after noncardiac surgery: a retrospective cohort study. Anesthesia & Analgesia 2014;119(3):522-32.

Taghipour B, SHARIF NH, Kaveh H, et al. Clinical manifestations of myocardial infarction in diabetic and non-diabetic patients. 2014.

Stein GY, Herscovici G, Korenfeld R, et al. Type-II myocardial infarction–patient characteristics, management and outcomes. PloS one 2014;9(1):e84285.

O'Donovan K. ACE inhibitors in the treatment of heart failure with reduced ejection fraction. Nurse Prescribing 2014;12(6):284-91.

Wachs TD, Georgieff M, Cusick S, McEwen BS. Issues in the timing of integrated early interventions: contributions from nutrition, neuroscience, and psychological research. Annals of the New York Academy of Sciences 2014;1308(1):89-106.

Wallander JL, Bann CM, Biasini FJ, et al. Development of children at risk for adverse outcomes participating in early intervention in developing countries: a randomized controlled trial. Journal of Child Psychology and Psychiatry 2014;55(11):1251-59.

Masenga SK, Kirabo A. Hypertensive heart disease: risk factors, complications and mechanisms. Frontiers in Cardiovascular Medicine 2023;10.

Gattringer T, Niederkorn K, Seyfang L, et al. Myocardial infarction as a complication in acute stroke: results from the austrian stroke unit registry. Cerebrovascular diseases 2014;37(2):147-52.

Smith SM, Huo T, Delia Johnson B, et al. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI‐sponsored WISE study. Journal of the American Heart Association 2014;3(1):e000660.

Mulè G, Calcaterra I, Nardi E, Cerasola G, Cottone S. Metabolic syndrome in hypertensive patients: an unholy alliance. World journal of cardiology 2014;6(9):890.

Ponticos M, Smith BD. Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. Journal of biomedical research 2014;28(1):25.

Jay Widmer R, Lerman A. Endothelial dysfunction and cardiovascular disease. Global Cardiology Science and Practice 2014;2014(3):43.

Tziomalos K, Karagiannis A, G Athyros V. Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure. Current Pharmaceutical Design 2014;20(40):6306-13.

Landini L. Modification of lifestyle factors are needed to improve the metabolic health of patients with cardiovascular disease risk. Current Pharmaceutical Design 2014;20(39):6078-88.

Mozos I. Ventricular arrhythmia risk in noncardiac diseases. Cardiac arrhythmias. Mechanisms, pathophysiology and treatment. Croatia: In Tech 2014:89-109.

Adameova A, Shah AK, Dhalla NS. Role of oxidative stress in the genesis of ventricular arrhythmias. International Journal of Molecular Sciences 2020;21(12):4200.

Lip GY, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: a consensus document from the European heart rhythm association (EHRA) and ESC Council on hypertension, endorsed by the heart rhythm Society (HRS), Asia-Pacific heart rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca Y Electrofisiología (SOLEACE). Ep Europace 2017;19(6):891-911.

Rifqi S, Permitasari DA. Advance of the Anticoagulant Co-therapy in STE-ACS Patient: Role of Enoxaparin. Update on Management of 2019:201.

Cipolla MJ, Liebeskind DS, Chan S-L. The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation. Journal of Cerebral Blood Flow & Metabolism 2018;38(12):2129-49.

Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation 2019;139(18):e891-e908.

Toell T, Boehme C, Mayer L, et al. Pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack–study protocol. BMC neurology 2018;18:1-10.

Boehme C, Domig L, Komarek S, et al. Long-term outcome of a pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack: study protocol. BMC Cardiovascular Disorders 2022;22(1):347.

Nair R, Johnson M, Kravitz K, et al. Characteristics and outcomes of early recurrent myocardial infarction after acute myocardial infarction. Journal of the American Heart Association 2021;10(16):e019270.

Masana L, Ros E, Sudano I, et al. Is there a role for lifestyle changes in cardiovascular prevention? What, when and how? Atherosclerosis Supplements 2017;26:2-15.

Doughty KN, Del Pilar NX, Audette A, Katz DL. Lifestyle medicine and the management of cardiovascular disease. Current cardiology reports 2017;19:1-10.

Nwabuo CC, Vasan RS. Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy. Current hypertension reports 2020;22:1-18.

Halle M, Esefeld K, Schindler M, Schunkert H. Exercise hypertension: Link to myocardial fibrosis in athletes?: SAGE Publications Sage UK: London, England; 2020. p. 89-93.

Schimmel K, Ichimura K, Reddy S, Haddad F, Spiekerkoetter E. Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target. Frontiers in Cardiovascular Medicine 2022;9:886553.

Jekell A, Nilsson PM, Kahan T. Treatment of hypertensive left ventricular hypertrophy. Current pharmaceutical design 2018;24(37):4391-96.

Katsi V, Georgiopoulos G, Laina A, et al. Left ventricular ejection fraction as therapeutic target: is it the ideal marker? Heart Failure Reviews 2017;22:641-55.

Association AD. 5. Lifestyle management: standards of medical care in diabetes—2019. Diabetes care 2019;42(Supplement_1):S46-S60.

Rippe JM, Angelopoulos TJ. Lifestyle strategies for risk factor reduction, prevention and treatment of cardiovascular disease. Lifestyle Medicine, Third Edition 2019:19-36.

DOI: https://doi.org/10.24815/jds.v9i1.40338